A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Trial Profile

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Adverse reactions; Registrational
  • Acronyms GLACIAL
  • Sponsors Genentech
  • Most Recent Events

    • 05 Mar 2018 Results of post hoc analysis examining treatment with omalizumab in subgroups defined by patient demographics with respect to the change from baseline to end of study in whole blood histamine or percentage circulating basophils presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 13 Jul 2016 Results of angioedema prevalence from three pivotal studies (ASTERIA I, ASTERIA II and GLACIAL) published in the Annals of Allergy, Asthma and Immunology
    • 16 Oct 2015 Results assessing response pattern of this and two other trials (ASTERIA-I and ASTERIA-II) published in the Journal of Allergy and Clinical Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top